S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$19.00
$19.00
50-Day Range
$18.20
$19.00
52-Week Range
$8.82
$21.86
Volume
N/A
Average Volume
1.36 million shs
Market Capitalization
$794.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.13

Intercept Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
27.0% Upside
$24.13 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.13
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to $1.93 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

755th out of 939 stocks

Biotechnology Industry

13th out of 21 stocks

ICPT stock logo

About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

ICPT Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Alfasigma To Acquire Intercept Pharma Fo $19 Per Share In Cash
See More Headlines
Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
341
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.13
High Stock Price Target
$54.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+27.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$221.82 million
Pretax Margin
-18.09%

Debt

Sales & Book Value

Annual Sales
$285.71 million
Book Value
$1.72 per share

Miscellaneous

Free Float
39,192,000
Market Cap
$794.77 million
Optionable
Optionable
Beta
0.88
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Jerome B. Durso (Age 55)
    President, CEO & Director
    Comp: $1.37M
  • Mr. Andrew Saik (Age 54)
    Chief Financial Officer
    Comp: $888.6k
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel
    Comp: $812.55k
  • Ms. Linda M. Richardson (Age 59)
    Executive VP & Chief Commercial Officer
    Comp: $837.73k
  • Dr. M. Michelle Berrey M.D. (Age 56)
    M.P.H., President of Research & Development and Chief Medical Officer
    Comp: $1.12M
  • Mr. Rocco Venezia (Age 47)
    Chief Accounting Officer & Treasurer
    Comp: $660.62k
  • Mr. Nareg Sagherian
    Executive Director of Global Investor Relations
  • Mr. David Ford (Age 53)
    Chief Human Resources Officer
    Comp: $434.9k
  • Dr. Mark Pruzanski M.D. (Age 55)
    Founder, Advisor & Director
    Comp: $1.3M
  • Paul Nitschmann
    Senior Vice President of Regulatory Affairs

ICPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ICPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View ICPT analyst ratings
or view top-rated stocks.

What is Intercept Pharmaceuticals' stock price target for 2024?

7 Wall Street analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price targets range from $14.00 to $54.00. On average, they predict the company's stock price to reach $24.13 in the next year. This suggests a possible upside of 27.0% from the stock's current price.
View analysts price targets for ICPT
or view top-rated stocks among Wall Street analysts.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analyst estimates of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 77.48% and a negative net margin of 19.39%. The firm's revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.68) EPS.

What ETF holds Intercept Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.00%), Balyasny Asset Management L.P. (0.00%), Harvest Management LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%), Simplex Trading LLC (0.00%) and Wolverine Asset Management LLC (0.00%).
View institutional ownership trends
.

This page (NASDAQ:ICPT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners